This technology provides a non-invasive method for early detection of cognitive diseases using spectroscopic analysis of saliva samples combined with advanced statistical and neural network models.
Background: Cognitive diseases such as Alzheimer's and mild cognitive impairment (MCI) represent significant challenges in healthcare due to their subtle early symptoms and the difficulty of timely diagnosis. Traditional diagnostic methods often rely on invasive procedures, costly imaging, or subjective clinical assessments, which can delay effective treatment and intervention. Recognizing the need for a more accessible and accurate diagnostic approach, researchers developed a system that leverages saliva—a readily obtainable biofluid—and advanced spectroscopic analysis to identify disease-specific biomarkers.
Technology Overview: This innovative technology employs spectroscopic techniques, including Raman and Fourier Transform Infrared (FTIR) spectroscopy, to analyze saliva samples and generate unique spectroscopic signatures corresponding to various cognitive conditions. By capturing the molecular composition reflected in these signatures, the system translates biological changes associated with cognitive diseases into measurable data. A key feature of this approach is the integration of a sophisticated computing system that uses neural networks and predetermined statistical models to interpret the spectroscopic data. These models have been trained to correlate specific spectral patterns with cognitive states such as healthy, Alzheimer's disease, or mild cognitive impairment. This process enables objective classification based on biochemical markers rather than solely clinical observation. The system design includes a spectroscopy device optimized for saliva analysis, enhancing ease of sample collection and testing. Additionally, the use of machine learning algorithms allows continuous improvement and calibration of the detection accuracy as more data becomes available. Overall, this technology offers a rapid, non-invasive, and scalable solution for early cognitive disease detection, potentially transforming patient care by facilitating timely diagnosis and personalized treatment planning.
https://suny.technologypublisher.com/files/sites/adobestock_194754842.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Non-invasive testing using saliva samples, improving patient comfort and compliance. • Rapid and accurate detection through advanced spectroscopic analysis combined with neural networks. • Ability to distinguish between healthy, Alzheimer's, and mild cognitive impairment conditions effectively. • Reduced reliance on costly and invasive diagnostic procedures like imaging or biopsies. • Scalable and adaptable system capable of continuous learning and improvement with additional data. • Potential to facilitate earlier diagnosis, enabling timely intervention and better patient outcomes.
Applications: • Clinical screening and early diagnosis of cognitive impairments such as Alzheimer's disease and MCI. • Monitoring disease progression and response to treatment in patients with cognitive disorders. • Use in healthcare settings as a cost-effective alternative to traditional diagnostic methods. • Integration into routine health check-ups for populations at risk of cognitive decline. • Research tool for understanding biochemical markers associated with cognitive diseases.
Intellectual Property Summary: Patent application filed 17/368,251
Stage of Development: TRL 4
Licensing Status: This technology is available for licensing.